With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13484-40-7,1-(2-Methoxyethyl)piperazine,as a common compound, the synthetic route is as follows.
Example 18; iV”-(2-Ammophenyl)-4-(3-chloro-5-{[4-(2-methoxyethyl)piperazin-l-yl]niethyl}pyridin-2- yl)benzamide; A solution of tert-bvyl (2-{[4-(3-chloro-5-formylpyridin-2- yl)benzoyl]amino}phenyl)carbamate (Method 1; 181 mg, 0.40 mmol) in dichloromethane (4 ml) was added to l-(2-methoxyethyl)piperazine (102 mg, 0.70 mmol). The reaction mixture was stirred for 5 minutes before addition of titanium (IV) isopropoxide (240 mul, 0.8 mmol). The reaction was allowed to stir at ambient temperature for 2 hours then sodium borohydride (61 mg, 1.60 mmol), added followed by methanol (0.4 ml). The reaction mixture was stirred for 2 hours then a further portion of sodium borohydride (61 mg, 1.60 mmol) added the reaction mixture was left to stir overnight (20 hours). Saturated aqueous sodium hydrogencarbonate solution (5 ml) was added, followed by water (5 ml) and dichloromethane (5 ml). The mixture was stirred for 30 minutes and the organic phase separated by filtration through an 1ST phase separating cartridge, and the aqueous extracted again with dichloromethane. The combined organic extracts were evaporated to dryness and the residue purified by flash chromatography on silica eluting with ethyl acetate followed by a rising gradient of methanol in ethyl acetate (0-20% v/v) to afford the protected product. This was taken up in dichloromethane (3 ml) and treated with trifiuoroacetic acid (1 ml) then at ambient temperature for 22 hrs. The reaction mixture was diluted with dichloromethane and poured onto an SCX-2 cartridge (5g). The cartridge was washed with dichloromethane (25 ml) and methanol (50 ml) before eluting products with a 2M solution of ammonia in methanol (50 ml). The ammoniacal fraction was evaporated to dryness and the resultant residue triturated with diethyl ether/isohexane to afford the title compound (78 mg, 41%); MMR Spectrum: (CDCl3) delta 2.61 (m, 10H), 3.35 (s, 3H), 3.53 (t, 2H), 3.58 (s, 2H), 3.88 (s, 2H), 6.87 (m, 2H), 7.11 (m, IH), 7.38 (d, IH), 7.84 (d, 2H), 7.88 (s, 2H), 8.00 (d, 2H), 8.53 (s, IH); Mass Spectrum: M+H+ (35Cl) 480.
13484-40-7, The synthetic route of 13484-40-7 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2006/75160; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics